沙立度胺单独及联合多柔比星对人肝癌细胞株HepG2过氧化物酶体增殖物激活受体γ、环氧合酶-2表达的影响  被引量:2

The Effects of Thalidomide Combined with Doxorubicin on PPARγ and COX-2 Expression of Human Hepatoma Cell Lines

在线阅读下载全文

作  者:韩亚光[1] 麻丽军[1] 崔彦芝[2] 曹世堂[1] 付华斌[1] 张建军[1] 

机构地区:[1]解放军白求恩国际和平医院256临床部内科,河北正定050800 [2]南方医科大学南方医院肿瘤中心,广州510515

出  处:《华北国防医药》2009年第2期24-27,共4页Medical Journal of Beijing Military Region

摘  要:目的:观察沙立度胺(Thalidomide,Tha)单独及联合多柔比星(Doxorubicin)对人肝癌细胞株HepG2细胞过氧化物酶体增殖物激活受体γ(peroxisome proliferator-activated receptorγ,PPARγ)、环氧合酶-2(cyclooxygenase-2,COX-2)表达的影响。方法:常规培养人肝癌细胞株HepG2并随机分成4组:空白对照组,沙立度胺组(200mg/L),多柔比星组(1.0mg/L),联合用药组(沙立度胺200mg/L+多柔比星1.0mg/L),分别作用于HepG2细胞12、24、48、72h后,应用免疫细胞化学法观察PPARγ、COX-2表达的影响。结果:沙立度胺单独及联合多柔比星可上调PPARγ,并降低COX-2表达,与对照组及多柔比星组差异有统计学意义(P<0.05)。结论:沙立度胺单独及联合多柔比星对人肝癌细胞株PPARγ、COX-2表达有明显作用,可能是沙立度胺抗肿瘤机制之一。Objective:To investigate the effects of Thalidomide alone and combined with Doxorubicin on the expressions of peroxisome proliferator-activated receptor-γ (PPARγ) and cyclooxygenase-2 (COX-2) in human hepatoma cell lines HepG2 in vitro. Methods: The HepG2 were randomly divided into 4 groups:untreated control group ;Thalidomide 200 mg/L group. Doxorubicin 1.0 mg/L and Thalidomide combined with Doxorubicin group. After H epG2 cells'treated for 12,24,48,72 hours in vitro by the conditions as described above,the effects of treatments were studied by modulation of gene expression of PPARγ,COX-2 immuoeytochemistry. Results: The results of immuocytoehemical technique showed that Thalidomide 200 mg/L alon.e and combined with Doxoruhicin 1.0 mg/L could up-regulate the expression of PPARγ and down-regulate the expression of COX-2 in human hepatoma cell lines HepG2 in vitro with statistical significance ( P 〈 0.05). Conclusion:Thalidomide alone and combined with Doxorubicin can obviously increase PPARγ expression, decrease COX-2 gene expression in HepG2 cell lines in vitro,which may be one of the possible molecular antitumor mechanisms of Thalidomide.

关 键 词:沙立度胺 多柔比星 肝肿瘤 HepG2 过氧化物酶体增殖物激活受体Γ 环氧合酶-2 基因表达调控 肿瘤 

分 类 号:R979.1[医药卫生—药品] R735.7[医药卫生—药学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象